Press release 📈 Stocks 🌍 United States

Relmada Therapeutics Appoints Jørn Skibsted Jakobsen as Chief Development Officer

Relmada Therapeutics adds former Ferring Pharmaceuticals executive Jørn Skibsted Jakobsen to its leadership team to spearhead the Phase 3 SPECTRUM registrational program for its lead bladder cancer candidate, NDV-01.

🕐 1 min read

1 assets impacted. Net bias: 0 Bullish, 0 Bearish, 1 Neutral. Strongest signal: RLMD → 2/10 (50% confidence).

📊 Affected Assets (1)

RLMD
Neutral 🤖 50%
📅 Short-term 🌍 US · Explicit

Relmada announced the hiring of Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer, Urology & Uro-Oncology, citing his nine-year tenure at Ferring where he led the pivotal ADSTILADRIN program to FDA, EMA, PMDA and Health Canada approvals. This strengthens leadership ahead of the planned Phase 3 SPECTRUM program for NDV-01, but it is a personnel appointment without quantified financial or trial results, so it does not materially change the company's outlook by itself.

Catalysts
  • • Appointment of a new Chief Development Officer announced November 16, 2026
  • • Preparation to initiate the Phase 3 SPECTRUM registrational program for NDV-01
Risk Factors
  • • Relmada remains a clinical-stage company dependent on the success of NDV-01 and sepranolone trials
  • • The article notes potential delays or failure to initiate the planned Phase 3 SPECTRUM program

🎯 Key Takeaways

  • Jørn Skibsted Jakobsen joins Relmada as Chief Development Officer, Urology & Uro-Oncology, effective November 16, 2026.
  • Dr. Jakobsen previously led the global clinical development of ADSTILADRIN, which secured approvals from the FDA, EMA, PMDA, and Health Canada.
  • The new appointment supports Relmada's preparations to initiate the Phase 3 SPECTRUM registrational program for its lead candidate, NDV-01.

📝 Executive Summary

Relmada Therapeutics has appointed Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer for Urology & Uro-Oncology. Dr. Jakobsen, who previously spent nine years at Ferring Pharmaceuticals leading the ADSTILADRIN program, will oversee clinical development for the company's pipeline, including the upcoming Phase 3 SPECTRUM registrational program for NDV-01.

❓ FAQ

Who did Relmada Therapeutics hire as its new Chief Development Officer?

Jørn Skibsted Jakobsen, MD, PhD, a board-certified urologist who previously led the global clinical development of Ferring Pharmaceuticals' ADSTILADRIN, which received approvals from the FDA, EMA, PMDA and Health Canada for non-muscle invasive bladder cancer.

Why is this hire relevant to Relmada's pipeline?

Dr. Jakobsen will lead clinical development across Relmada's pipeline, including the planned Phase 3 SPECTRUM registrational program for its lead candidate NDV-01, bringing experience from a globally approved bladder cancer therapy.